# US 2012/0232225 A1 · Synthesis and isolation of dendrimer systems

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0232225 A1
- Document ID: US20120232225A1
- Status: Published application
- Kind: A1
- Application number: 13/392,421
- Filed: 2010-07-23
- Published: 2012-09-13
- Earliest claimed: 2009-08-26
- Assignees: The Regents of the University of Michigan
- Inventors: James R. Baker, JR.; Mark M. Banaszak Holl; Douglas Gurnett Mullen; Bradford G. Orr; Ankur Desai; Leonard M. Sander; Jack Neel Waddell
- Web page: https://patentgrep.com/patent/US20120232225A1

## CPC

- C08G 83/004: {After treatment of dendrimers}
- A61P 35/00: Antineoplastic agents
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel methods of synthesis and isolation of dendrimer systems. In particular, the present invention is directed to novel dendrimer conjugates with defined and limited numbers of ligand conjugates and high levels of structural uniformity, methods of synthesizing the same, compositions comprising the conjugates, as well systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, pain therapy, etc.)).

## Claims

### Claim at position 1

1-67. (canceled)

### Claim 68

A composition comprising ten or more dendrimer molecules having one or more ligands, wherein 80% or more of said dendrimer molecules having one or more ligands are structurally uniform.

### Claim at position 3

69-73. (canceled)

### Claim 74 (depends on 68)

The composition of claim 68, wherein said dendrimer molecules are PAMAM dendrimers.

### Claim 75

(canceled)

### Claim 76 (depends on 68)

The composition of claim 68, wherein said one or more ligands is configured for attachment with a conjugate via click chemistry.

### Claim 77

(canceled)

### Claim 78 (depends on 76)

The composition of claim 76, wherein said conjugate is selected from the group consisting of therapeutic agents, targeting agents, trigger agents, and imaging agents.

### Claim at position 9

79-85. (canceled)

### Claim 86 (depends on 68)

The composition of claim 68, wherein terminal branches of said ten or more dendrimer molecules comprise a blocking agent.

### Claim 87 (depends on 86)

The composition of claim 86, wherein said blocking agent comprises an acetyl group.

### Claim 88

A method of preparing dendrimer molecules having one or more ligands, comprising
a) conjugating a plurality of dendrimer molecules with one or more ligand molecules so as to yield a population of dendrimer molecules conjugated with one or more ligand molecules; and
b) using reverse phase HPLC to separate said population of dendrimer molecules conjugated with one or more ligand molecules into subpopulations of dendrimer molecules conjugated with one or more ligand molecules, wherein 80% or more of said dendrimer molecules conjugated with one or more ligand molecules within each subpopulation are structurally uniform.

### Claim at position 13

89-93. (canceled)

### Claim 94 (depends on 88)

The method of claim 88, further comprising quantitatively determining the number of ligand conjugations per dendrimer molecule.

### Claim 95 (depends on 94)

The method of claim 94, wherein said quantitative determination is performed by peak analysis.

### Claim 96 (depends on 88)

The method of claim 88, wherein said dendrimer molecules are PAMAM dendrimers.

### Claim 97

(canceled)

### Claim 98 (depends on 88)

The method of claim 88, wherein said one or more ligands is configured for attachment with a conjugate via click chemistry.

### Claim 99

(canceled)

### Claim 100 (depends on 98)

The method of claim 98, wherein said conjugate is selected from the group consisting of therapeutic agents, targeting agents, trigger agents, and imaging agents.

### Claim at position 21

101-107. (canceled)

### Claim 108 (depends on 88)

The method of claim 88, wherein terminal branches of said dendrimer molecules comprise a blocking agent.

### Claim 109 (depends on 108)

The method of claim 108, wherein said blocking agent comprises an acetyl group.

### Claim at position 24

110-111. (canceled)

### Claim 112

A product made by the process comprising:
a) conjugating a plurality of dendrimer molecules with one or more ligand molecules so as to yield a population of dendrimer molecules conjugated with one or more ligand molecules; and
b) using reverse phase HPLC to separate said population of dendrimer molecules conjugated with one or more ligand molecules into subpopulations of dendrimer molecules conjugated with one or more ligand molecules, wherein 80% or more of said dendrimer molecules conjugated with one or more ligand molecules within each subpopulation are structurally uniform.

### Claim at position 26

113-117. (canceled)

### Claim 118 (depends on 112)

The product of claim 112, wherein said plurality of dendrimer molecules comprise PAMAM dendrimers.

### Claim 119

(canceled)

### Claim 120 (depends on 112)

The product of claim 112, wherein said one or more ligand molecules is configured for attachment with a conjugate via click chemistry.

### Claim 121

(canceled)

### Claim 122 (depends on 120)

The product of claim 120, wherein said conjugate is selected from the group consisting of therapeutic agents, targeting agents, trigger agents, and imaging agents.

### Claim at position 32

123-129. (canceled)

### Claim 130 (depends on 112)

The product of claim 112, wherein said plurality of dendrimer molecules have terminal branches, wherein said terminal branches comprise a blocking agent.

### Claim 131 (depends on 130)

The product of claim 130, wherein said blocking agent comprises an acetyl group.
